arrow_back Back to App

Preventing shortages of critical drugs: faster reporting and supply chain transparency.

This law aims to prevent shortages of essential medicines, such as life-saving or emergency drugs. It requires manufacturers to quickly notify the government not only of production interruptions but also of sudden demand increases, allowing for earlier preventive action. Citizens will benefit from greater certainty regarding the availability of necessary treatments.
Key points
Manufacturers must report the risk of shortage for critical drugs (e.g., life-saving ones) within 10 business days if the cause is a sudden increase in demand or export restrictions.
Supply chains for key drug ingredients (APIs) must be reported twice a year, increasing transparency and supply stability.
The government must share information about potential drug shortages with patient and healthcare provider organizations for better preparation.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_2362
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2023-07-18
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-09-2025
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug Shortage Prevention Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_2362.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2023-07-18.

What are the main provisions?

Key points include:

  • Manufacturers must report the risk of shortage for critical drugs (e.g., life-saving ones) within 10 business days if the cause is a sudden increase in demand or export restrictions.
  • Supply chains for key drug ingredients (APIs) must be reported twice a year, increasing transparency and supply stability.
  • The government must share information about potential drug shortages with patient and healthcare provider organizations for better preparation.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health